Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients
Tumors act systemically to sustain cancer progression, affecting the physiological processes in the host and triggering responses in the blood circulating cells. In this study, we explored blood transcriptional patterns of patients with two subtypes of HER2 negative breast cancers, with different pr...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2016/3239167 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556211574145024 |
|---|---|
| author | Ovidiu Balacescu Loredana Balacescu Oana Virtic Simona Visan Claudia Gherman Flaviu Drigla Laura Pop Gabriela Bolba-Morar Carmen Lisencu Bogdan Fetica Oana Tudoran Ioana Berindan-Neagoe |
| author_facet | Ovidiu Balacescu Loredana Balacescu Oana Virtic Simona Visan Claudia Gherman Flaviu Drigla Laura Pop Gabriela Bolba-Morar Carmen Lisencu Bogdan Fetica Oana Tudoran Ioana Berindan-Neagoe |
| author_sort | Ovidiu Balacescu |
| collection | DOAJ |
| description | Tumors act systemically to sustain cancer progression, affecting the physiological processes in the host and triggering responses in the blood circulating cells. In this study, we explored blood transcriptional patterns of patients with two subtypes of HER2 negative breast cancers, with different prognosis and therapeutic outcome. Peripheral blood samples from seven healthy female donors and 29 women with breast cancer including 14 triple-negative breast cancers and 15 hormone-dependent breast cancers were evaluated by microarray. We also evaluated the stroma in primary tumors. Transcriptional analysis revealed distinct molecular signatures in the blood of HER2− breast cancer patients according to ER/PR status. Our data showed the implication of immune signaling in both breast cancer subtypes with an enrichment of these processes in the blood of TNBC patients. We observed a significant alteration of “chemokine signaling,” “IL-8 signaling,” and “communication between innate and adaptive immune cells” pathways in the blood of TNBC patients correlated with an increased inflammation and necrosis in their primary tumors. Overall, our data indicate that the presence of triple-negative breast cancer is associated with an enrichment of altered systemic immune-related pathways, suggesting that immunotherapy could possibly be synergistic to the chemotherapy, to improve the clinical outcome of these patients. |
| format | Article |
| id | doaj-art-ae31503c8598426f90df66f375c6d888 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-ae31503c8598426f90df66f375c6d8882025-02-03T05:46:03ZengWileyMediators of Inflammation0962-93511466-18612016-01-01201610.1155/2016/32391673239167Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers PatientsOvidiu Balacescu0Loredana Balacescu1Oana Virtic2Simona Visan3Claudia Gherman4Flaviu Drigla5Laura Pop6Gabriela Bolba-Morar7Carmen Lisencu8Bogdan Fetica9Oana Tudoran10Ioana Berindan-Neagoe11Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, RomaniaDepartment of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, RomaniaResearch Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy “I. Hatieganu”, 23 Marinescu Street, 400337 Cluj-Napoca, RomaniaDepartment of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, RomaniaDepartment of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, RomaniaDepartment of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, RomaniaResearch Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy “I. Hatieganu”, 23 Marinescu Street, 400337 Cluj-Napoca, RomaniaDepartment of Senology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, RomaniaDepartment of Imagistics, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, RomaniaDepartment of Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, RomaniaDepartment of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, RomaniaDepartment of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, RomaniaTumors act systemically to sustain cancer progression, affecting the physiological processes in the host and triggering responses in the blood circulating cells. In this study, we explored blood transcriptional patterns of patients with two subtypes of HER2 negative breast cancers, with different prognosis and therapeutic outcome. Peripheral blood samples from seven healthy female donors and 29 women with breast cancer including 14 triple-negative breast cancers and 15 hormone-dependent breast cancers were evaluated by microarray. We also evaluated the stroma in primary tumors. Transcriptional analysis revealed distinct molecular signatures in the blood of HER2− breast cancer patients according to ER/PR status. Our data showed the implication of immune signaling in both breast cancer subtypes with an enrichment of these processes in the blood of TNBC patients. We observed a significant alteration of “chemokine signaling,” “IL-8 signaling,” and “communication between innate and adaptive immune cells” pathways in the blood of TNBC patients correlated with an increased inflammation and necrosis in their primary tumors. Overall, our data indicate that the presence of triple-negative breast cancer is associated with an enrichment of altered systemic immune-related pathways, suggesting that immunotherapy could possibly be synergistic to the chemotherapy, to improve the clinical outcome of these patients.http://dx.doi.org/10.1155/2016/3239167 |
| spellingShingle | Ovidiu Balacescu Loredana Balacescu Oana Virtic Simona Visan Claudia Gherman Flaviu Drigla Laura Pop Gabriela Bolba-Morar Carmen Lisencu Bogdan Fetica Oana Tudoran Ioana Berindan-Neagoe Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients Mediators of Inflammation |
| title | Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients |
| title_full | Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients |
| title_fullStr | Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients |
| title_full_unstemmed | Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients |
| title_short | Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients |
| title_sort | blood genome wide transcriptional profiles of her2 negative breast cancers patients |
| url | http://dx.doi.org/10.1155/2016/3239167 |
| work_keys_str_mv | AT ovidiubalacescu bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients AT loredanabalacescu bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients AT oanavirtic bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients AT simonavisan bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients AT claudiagherman bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients AT flaviudrigla bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients AT laurapop bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients AT gabrielabolbamorar bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients AT carmenlisencu bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients AT bogdanfetica bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients AT oanatudoran bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients AT ioanaberindanneagoe bloodgenomewidetranscriptionalprofilesofher2negativebreastcancerspatients |